Technical Analysis for AKCA - Akcea Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
AKCA closed down 1.97 percent on Monday, October 15, 2018, on 88 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 5
|See historical AKCA trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 15||Calm After Storm||Range Contraction||0.00%|
|Oct 15||Narrow Range Bar||Range Contraction||0.00%|
|Oct 15||NR7||Range Contraction||0.00%|
|Oct 15||Wide Bands||Range Expansion||0.00%|
|Oct 15||Down 3 Days in a Row||Weakness||0.00%|
|Oct 15||Down 4 Days in a Row||Weakness||0.00%|
|Oct 15||Oversold Stochastic||Weakness||0.00%|
|Oct 12||Fell Below 200 DMA||Bearish||-1.97%|
|Oct 12||Wide Bands||Range Expansion||-1.97%|
|Oct 12||Down 3 Days in a Row||Weakness||-1.97%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more AKCA news...
|52 Week High||40.75|
|52 Week Low||15.2|
|200-Day Moving Average||25.377|
|50-Day Moving Average||30.4556|
|20-Day Moving Average||30.072|
|10-Day Moving Average||28.275|
|Average True Range||2.7937|
|Chandelier Exit (Long, 3 ATRs )||29.3489|
|Chandelier Exit (Short, 3 ATRs )||30.9511|
|Upper Bollinger Band||37.8597|
|Lower Bollinger Band||22.2843|
|Percent B (%b)||0.04|
|MACD Signal Line||-0.1246|
|Market Cap||1.46 Billion|
|Num Shares||63.9 Million|
|Price-to-Earnings (P/E) Ratio||-12.09|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||24.58|
|Resistance 3 (R3)||24.67||24.20||24.29|
|Resistance 2 (R2)||24.20||23.76||24.15||24.19|
|Resistance 1 (R1)||23.52||23.49||23.29||23.43||24.10|
|Support 1 (S1)||22.37||22.61||22.14||22.28||21.60|
|Support 2 (S2)||21.90||22.34||21.85||21.51|
|Support 3 (S3)||21.22||21.90||21.41|
|Support 4 (S4)||21.13|